Navigation Links
Cappella Promotes Sideguard & Serial IVUS Analysis at JIM 2010
Date:2/19/2010

GALWAY, Ireland, Feb. 19 /PRNewswire/ -- Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, promoted their serial IVUS analysis & Sideguard® 3.25 device during the Joint Interventional Meeting (JIM) in Rome. Gary S. Mintz, MD, Cardiovascular Research Foundation, New York, USA presented "Positive Vessel Remodeling Using Sideguard in Coronary Bifurcations" during the New Technologies 1 Symposium. Dr. Mintz highlighted that serial IVUS & OCT are ongoing in the Sideguard 3 study to confirm the initial findings of Sideguard 1 and assess stent strut coverage. The IVUS sub-study results from Sideguard 1 were published in the American Journal of Cardiology in October 2009.

The newest addition to the Sideguard portfolio, the Sideguard 3.25, was implanted successfully in a live case performed by Ralf Mueller, MD, Siegburg, Germany. According to Dr. Mueller, "We implanted the Sideguard 3.25 stent together with a 3,0mm DES in a Medina 0,1,1 LAD/D1 stenosis.  Positioning was easy and precise and IVUS demonstrated excellent scaffolding at the bifurcation. The use of the Sideguard device made this bifurcation intervention easy and predictable with an optimal acute result."

Martin B. Leon, MD, Founder & Director of Transcatheter Cardiovascular Therapeutics (TCT) and Scientific Advisory Board member of Cappella assisted with the case. Dr. Leon expressed his satisfaction with the device, "It was the first time I used the 3.25 & I was very pleased with the outcome of the case."

About Cappella, Inc.

Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. Cappella's initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary arteries first, rather than the main vessel. More importantly, it allows the preferred stent of choice for the main vessel. An optimal stent design specific to the anatomy of the sidebranch, combined with the qualities of Nitinol now provide a dynamic solution for treating sidebranch disease. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc.  For more information, see: www.cappella-med.com.

SOURCE Cappella Inc.

Back to top

RELATED LINKS
http://www.cappella-med.com

'/>"/>

SOURCE Cappella Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Eamonn Hobbs Joins the Board of Directors at Cappella
2. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
3. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
4. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
5. PLAN C Agency Promotes Hepatitis B Awareness Through B HERE
6. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
7. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
8. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
9. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
10. Robbins & Myers Announces Regular Quarterly Cash Dividend
11. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Systemic Lupus Erythematosus ...  report to their offering.       ... The latest research Europe Systemic Lupus Erythematosus ... provides comprehensive insights into Systemic Lupus Erythematosus ...
(Date:5/4/2016)... an upgrade. There are many medical recorders on the market but none like this. ... HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned authorized reseller of the ... Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... ... Business Journalists , led by the Wharton School’s most prominent professors, help ... one-day program at the Wharton School’s San Francisco campus will feature Wharton ...
(Date:5/5/2016)... ... 05, 2016 , ... Derrin Doty Group has unveiled the latest charity campaign ... communities west of Seattle. The insurance provider’s caring team has been so moved by ... due to complications from the flu, that they have decided to extend their original ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/5/2016)... ... May 05, 2016 , ... Long Island’s fastest growing comprehensive eye care ... Island eye surgeon, Kathleen Van Valkenburg, MD as part of their ongoing effort to ... medical director and managing partner of North Shore Eye Care. , “We are ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade students ... , Director of Allergy and Asthma Clinical Research in the Division of Pulmonary, ...
Breaking Medicine News(10 mins):